Clinical application of contrast-enhanced ultrasound in prediction of microvascular invasion in hepatocellular carcinoma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100048230

Enrollment

Unknown

Registered

2021-07-05

Start date

2021-07-01

Completion date

Unknown

Last updated

2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Gold Standard:Clinical outcome

Index test:CEUS

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who came to our hospital for diagnosis and treatment due to suspected liver cancer; 2. Routine ultrasound and contrast-enhanced ultrasound examination; 3. Aged >18 years and <80 years; 4. Informed consent of patients was obtained for examination and treatment.

Exclusion criteria

Exclusion criteria: 1. The patient has previously received treatments such as radiofrequency ablation, interventional chemoembolization, surgery, and chemotherapy; 2. Pregnant women and lactating women; 3. The patient is allergic to eggs, milk, seafood, and ultrasound contrast agents, and cannot perform ultrasound contrast examination.

Design outcomes

Primary

Measure	Time frame
Characteristics of routine ultrasound in liver lesion;Characteristics of contrast-enhanced ultrasound in liver lesion;	—

Secondary

Measure	Time frame
Disease-free survival time;Overall survival time;	—

Countries

China

Contacts

Public ContactLuo Yukun

The First Medical Centre, Chinese PLA General Hospital

lyk301@163.com+86 10 66936848

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026